Milestone Pharmaceuticals Inc. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Milestone reported Q2 2026 results with $0.6M product revenue (vs. $0 in Q2 2025) and $0.8M for H1 2026. Insurance coverage for CARDAMYST expanded from ~25% to ~50% of commercially insured lives following new formulary agreements with UnitedHealthcare and others. Prescribers grew from ~200 (end-Q1) to >800 (end-Q2), with >1,500 scripts filled for >1,300 patients. The company activated first sites in Phase 3 ReVeRA-301 trial for AFib-RVR indication. Cash position strengthened to $170.6M (from $106.0M at year-end 2025), providing runway into H2 2027. SG&A nearly tripled to $22.6M in Q2 2026 ($8.9M in Q2 2025) due to launch expenses; net loss widened to $28.6M for Q2 2026.
Why this rating
Early-stage commercial traction and insurance gains are encouraging; however, revenue ($0.8M H1) is minimal relative to ~$99M market cap, and burn rate ($54.7M H1 loss) remains substantial. Meaningful but not transformational.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.